This site is no longer being updated. Data are accurate as of 2 Dec 2022.

Vector State Research Center of Virology and Biotechnology: EpiVacCorona

Vector State Research Center of Virology and Biotechnology: EpiVacCorona

Vaccine Type: Protein Subunit

About Trial Phases

Phase 1: 1 Trial

NCT04527575
Russian Federation

Phase 2: 1 Trial

NCT04527575
Russian Federation

Phase 3: 2 Trials

NCT04780035
Russian Federation
NCT05021016
Russian Federation

Approvals

4 Countries

Registered Trials

NCT04780035
Phase 3
Russian Federation
Total Enrollment: 3,000
Official Trial Registration:
- NCT04780035(Opens in new tab/window)
NCT05021016
Phase 3
Russian Federation
Total Enrollment: 150
Official Trial Registration:
- NCT05021016(Opens in new tab/window)
NCT04527575
Phase 1/2
Russian Federation
Total Enrollment: 100
Official Trial Registration:
- NCT04527575(Opens in new tab/window)

© 2023 VIPER Group COVID19 Vaccine Tracker Team

Funding provided by the McGill University Interdisciplinary Initiative in Infection and Immunity (MI4)

This site is provided for informational purposes only based on publically available data.

Site Credits Website Feedback Form